Clinical trials: Angina Pectoris
Stable Angina
Correlational Study on the Biomarkers Application to the Prediction and Diagnosis of Cardiovascular Diseases
Through the literature review , we pick out a series of forward-looking biological indicators as follows : 1. NGAL 2. Cystatin C: 3. Galectin-3: 4. Copeptin: 5. MR-Pro ANP: 6. sST2:
- Trial name
- NCT02179047
- Testing
- coronary angiography
- Where
- Taiwan
- Volunteers
- 214 people
- Sponsor
- Taipei City Hospital
Ischemia, Angina
PrEssure wiRe Compared to Microcatheter-based Sensing Technology For the Evaluation of FFR Measurements
The model by which physicians measure the lack of blood flow in the vessels that supply blood to the heart muscle is called Fractional Flow Reserve (FFR).
- Trial name
- PERFORM (NCT02648230)
- Testing
- St. Jude Medical Pressure Wire, ACIST Navvus Microcatheter
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Columbia University
Myocardial Infarction, Heart Failure
The Improving ATTENDance to Cardiac Rehabilitation Trial
The benefits of cardiac rehabilitation are well known. However, despite center based cardiac rehabilitation (CBCR) representing guideline-based care for patients with cardiovascular disease, most patients do not complete the…
- Conditions
- Myocardial Infarction, Heart Failure, Heart Valve Diseases, Cardiac Event
- Trial name
- iATTEND (NCT03646760)
- Testing
- HYCR, CBCR
- Where
- United States
- Volunteers
- 282 people
- Sponsor
- Henry Ford Health System
Stable Angina
Outcome of Coronary High Angulated Bifurcation Lesions Treated With Kissing Ballooning or Sequential Ballooning Techniques
Coronary artery bifurcation lesions prone to occur with the worsening of atherosclerosis. Their structural properties make angioplasty technique to increase the difficulty of implementation, but also increased the risks of the…
- Trial name
- MV:main branch (NCT02137486)
- Where
- Taiwan
- Volunteers
- 214 people
- Sponsor
- Taipei City Hospital
Refractory Angina
Study Protocol of Intramyocardial Injection of Autologous Bone Marrow Stem Cells for Refractory Angina
Therapeutic neovascularization is an innovative strategy for cardiac tissue recovery due to chronic, intense ischemia. Thus stem cell therapy has become a promising procedure for the large number of patients with refractory…
- Trial name
- ReACT (NCT01966042)
- Testing
- Local sedation, Bone Marrow Aspiration, Minithoracotomy
- Where
- Brazil
- Volunteers
- 13 people
- Sponsor
- CellPraxis Bioengenharia Ltda.
Chronic Stable Angina
Effects of Ranolazine and Exercise on Daily Physical Activity Trial
The primary objective is to assess whether the increased angina threshold on ranolazine and subsequent higher training intensity will result in improved exercise tolerance and oxygen consumption; and greater than that observed…
- Trial name
- EREDA (NCT01948310)
- Testing
- Ranolazine, Aerobic Exercise
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Duke University
Class IV Angina
Cardiogenesis Transmyocardial Revascularization Registry
The objectives of the registry are as follows: Track "real world" performance outcomes and physician experience using the Cardiogenesis Laser System; Further define the disease characteristics of the population being treated…
- Trial name
- ANGINA RELIEF (NCT01827319)
- Where
- 24 sites in United States
- Volunteers
- 203 people
- Sponsor
- Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.
Stable Angina, Heart Failure
Plasmonic Nanophotothermal Therapy of Atherosclerosis
The investigators hypothesize that the nanoburning is a very challenging technique to demolish and reverse the plaque especially in combination with stem cell technologies promising the functional restoration of the vessel wall.
- Conditions
- Stable Angina, Heart Failure, Atherosclerosis, Multivessel Coronary Artery Disease
- Trial name
- NANOM-FIM (NCT01270139)
- Testing
- Transplantation of nanoparticles, Transplantation of iron-bearing nanoparticles, Stenting
- Where
- 4 sites in Netherlands, Russia
- Volunteers
- 180 people
- Sponsor
- Ural State Medical University
Coronary Artery Disease, Atherosclerosis, Coronary
Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
The objective of this post-approval study is to confirm that the clinical performance of the Orsiro stent in a real-world setting is similar to the clinical performance observed for Orsiro in the BIOFLOW-V Investigational Device…
- Conditions
- Coronary Artery Disease, Atherosclerosis, Coronary, Myocardial Ischemia, Ischemic Heart Disease
- Trial name
- BIOFLOW-VII (NCT04175626)
- Testing
- Orsiro DES
- Where
- 33 sites in United States
- Volunteers
- 556 people
- Sponsor
- Biotronik, Inc.
Hypercholesterolemia, Myocardial Infarction
IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)
This is a randomized, active-control, double-blind study of subjects with stabilized high-risk acute coronary syndrome (ACS). The primary objective is to evaluate the clinical benefit of Ezetimibe/Simvastatin Combination 10/40…
- Trial name
- NCT00202878
- Testing
- ezetimibe/simvastatin, simvastatin
- Volunteers
- 18,144 people
- Sponsor
- Organon and Co
Prevention & Control
Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
The primary objectives of this study are: To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction…
- Trial name
- COMPASS (NCT01776424)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Pantoprazole
- Where
- 565 sites in United States, Argentina and 31 more
- Volunteers
- 27,395 people
- Sponsor
- Bayer
Stable Angina
Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina
In this study the investigators will use careful scientific blinding of patient and their subsequent healthcare staff so that the investigators can determine exactly how much difference coronary angioplasty makes to symptoms and…
- Trial name
- ORBITA (NCT02062593)
- Testing
- Coronary angioplasty
- Where
- 5 sites in United Kingdom
- Volunteers
- 230 people
- Sponsor
- Imperial College London
Hypertrophic Cardiomyopathy
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
The primary objective of this study was to evaluate the effect of eleclazine (GS-6615) on exercise capacity as measured by Peak oxygen uptake (VO2) achieved during cardiopulmonary exercise testing (CPET), in participants with…
- Trial name
- LIBERTY-HCM (NCT02291237)
- Testing
- Eleclazine
- Where
- 46 sites in United States, Australia and 6 more
- Volunteers
- 172 people
- Sponsor
- Gilead Sciences
Ischemic Heart Disease, Angina Pectoris
XIENCE PRIME SV Everolimus Eluting Coronary Stent Japan Post Marketing Surveillance (XIENCE PRIME SV Japan PMS)
The objective of the study is to evaluate the safety and efficacy of XIENCE PRIME SV in real world practice in Japanese hospitals.
- Conditions
- Ischemic Heart Disease, Angina Pectoris, Coronary Artery Disease, Coronary Artery Occlusion
- Trial name
- NCT02513719
- Testing
- XIENCE PRIME SV Everolimus Eluting Coronary Stent
- Where
- 33 sites in Japan
- Volunteers
- 312 people
- Sponsor
- Abbott Medical Devices
Diabetes, Type I, Diabetes, Type II
Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD
Coronary vascular dysfunction is highly prevalent among patients with known or suspected Coronary Artery Disease (CAD)1, increases the severity of inducible myocardial ischemia (beyond the effects of upstream coronary…
- Conditions
- Diabetes, Type I, Diabetes, Type II, Angina, Coronary Artery Disease
- Trial name
- RAND-CFR (NCT01754259)
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Brigham and Women's Hospital
Unstable Angina, Myocardial Infarction
Early Versus Delayed Timing of Intervention in Patients With Acute Coronary Syndromes
The timing of intervention study is a prospective, randomized, international, multicentre comparison of the relative efficacy, safety, and cost effectiveness of a management strategy of coronary angiography and intervention…
- Trial name
- TIMACS (NCT00552513)
- Testing
- Early Coronary Intervention, Delayed Coronary Intervention
- Where
- Canada
- Volunteers
- 3,031 people
- Sponsor
- Population Health Research Institute
Coronary Artery Disease, Angina, Unstable
Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)
This is a phase II multi-centre study in 140 patients undergoing elective PCI to obtain the information on dose-response of argatroban in pharmacodynamic markers and to assess the anticoagulation, safety and efficacy of…
- Trial name
- NCT00508924
- Testing
- Argatroban, Heparin
- Where
- 8 sites in Belgium, Germany
- Volunteers
- 140 people
- Sponsor
- Tanabe Pharma Corporation
Chest Pain, Coronary Artery Disease
ARgentinean Risk Assessment Registry in ACS; the ARRA-RACS Study
The first aim of this trial is to assess the long-term prognostic value of Omega-3 index, which is a measure of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) relative to other fatty acids in the erythrocyte membrane…
- Conditions
- Chest Pain, Coronary Artery Disease, Unstable Angina Pectoris, Myocardial Infarction
- Trial name
- ARRA-RACS (NCT01377402)
- Where
- 10 sites in Argentina, Norway
- Volunteers
- 982 people
- Sponsor
- Helse Stavanger HF
Acute Coronary Syndrome
A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects
This study will evaluate the relative efficacy and safety of prasugrel and clopidogrel in a medically managed Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) acute coronary syndrome (ACS) population (that is…
- Trial name
- TRILOGY ACS (NCT00699998)
- Testing
- Clopidogrel, Prasugrel, Commercially-available Aspirin
- Where
- 688 sites in United States, Argentina and 51 more
- Volunteers
- 9,326 people
- Sponsor
- Eli Lilly and Company
Acute Coronary Syndrome (ACS)
Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)
This Phase IV, multicenter trial is designed to assess the efficacy of prasugrel in preventing the formation of blood clots in Taiwanese patients with ACS who have been treated with PCI.
- Trial name
- NCT03672097
- Testing
- Prasugrel
- Where
- 10 sites in Taiwan
- Volunteers
- 204 people
- Sponsor
- Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company